A total of 304 men were excluded due to several reasons as follows: 5 previously received a PCa diagnosis, 114 had a secondary prostate biopsy twice or higher, 2 received some kind of hormonal treatment except for 5a-reductase inhibitor, 57 were older than 80 years, and 126 patients had PSA levels ≥50 ng/mL. The gene discussed is KLK3; the disease is posterior cortical atrophy.